IN-VITRO AND IN-VIVO ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST MYCOBACTERIUM-TUBERCULOSIS

被引:65
|
作者
HIRATA, T
SAITO, H
TOMIOKA, H
SATO, K
JIDOI, J
HOSOE, K
HIDAKA, T
机构
[1] SHIMANE MED UNIV, DEPT MICROBIOL & IMMUNOL, IZUMO, SHIMANE 693, JAPAN
[2] SHIMANE MED UNIV, DEPT DERMATOL, IZUMO, SHIMANE 693, JAPAN
[3] NATL INST LEPROSY RES, TOKYO 189, JAPAN
[4] KANEKA CORP, BIOCHEM RES LABS, TAKASAGO, HYOGO 676, JAPAN
关键词
D O I
10.1128/AAC.39.10.2295
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro and in vivo activities of a new benzoxazinorifamycin, KRM-1648 (KRM), against Mycobacterium tuberculosis were studied. The MIC at which 50% of the isolates are inhibited (MIC(50)) and the MIC(90) of KRM for 30 fresh isolates of M. tuberculosis measured by the BACTEC 460 TB System,were 0.016 and 2 mu g/ml, respectively. These values were much lower than those for rifampin (RMP), which were 4 and >128 mu g/ml, respectively, and considerably lower than those for rifabutin (RBT), which were 0.125 and 8 mu g/ml, respectively. A correlational analysis of the MICs of these drugs for the clinical isolates revealed the presence of cross-resistance of the organisms to KRM and either RMP or RBT although the MICs of KRM were distributed over a much lower range than were those of the other two drugs. KRM and RMP at concentrations of 1 to 10 mu g/ml almost completely inhibited the bacterial growth of RMP-sensitive strains (H,,Rv, Kurono, and Fujii) of M. tuberculosis phagocytosed in macrophage-derived J774.1 cells. KRM was more active than RMP in inhibiting the growth of the RMP-resistant (MIC = 8 mu g/ml) Kurata strain but failed to show such an effect against the RMP-resistant (MIC > 128 mu g/ml) Watanabe strain. When KRM was given to M. tuberculosis-infected mice at dosages of 5 to 20 mg/kg of body weight by gavage, once daily six times per week from day 1 after infection, it was much more efficacious than RMP against infections induced in mice by the RMP-sensitive Kurono strain, as measured by a reduction of rates of mortality, a reduction of the frequency and extent of gross lung lesions, histopathological changes in lung tissues, and a decrease in the bacterial loads in the lungs and spleens of infected mice. KRM also displayed significant therapeutic efficacy against infection induced by the RMP-resistant Kurata strain, while neither KRM nor RMP was efficacious against infection by the RMP-resistant Watanabe strain. In the case of infection with the Kurono strain, the efficacy of the drugs in prolonging the time of survival was in the order KRM, RBT, RMP. KRM was much more efficacious than RMP, when given at 1- to 4-week intervals. These findings suggest that KRM may be useful for the clinical treatment of tuberculosis contracted through RMP-sensitive strains, even when it is administered at long intervals.
引用
收藏
页码:2295 / 2303
页数:9
相关论文
共 50 条
  • [1] ACTIVITY OF KRM-1648, A NEW BENZOXAZINORIFAMYCIN, AGAINST MYCOBACTERIUM-TUBERCULOSIS IN A MURINE MODEL
    KLEMENS, SP
    GROSSI, MA
    CYNAMON, MH
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) : 2245 - 2248
  • [2] ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AND ETHAMBUTOL AGAINST MYCOBACTERIUM-AVIUM COMPLEX IN-VITRO AND IN MACROPHAGES
    INDERLIED, CB
    BARBARABURNHAM, L
    WU, M
    YOUNG, LS
    BERMUDEZ, LEM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) : 1838 - 1843
  • [3] Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages
    Mor, N
    Simon, B
    Heifets, L
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1482 - 1485
  • [4] IN-VIVO ANTILEPROSY ACTIVITY OF THE NEWLY SYNTHESIZED BENZOXAZINORIFAMYCIN, KRM-1648
    TOMIOKA, H
    SAITO, H
    INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES, 1993, 61 (02) : 255 - 258
  • [5] IN-VITRO AND IN-VIVO ANTIBACTERIAL ACTIVITIES OF KRM-1648 AND KRM-1657, NEW RIFAMYCIN DERIVATIVES
    FUJII, K
    TSUJI, A
    MIYAZAKI, S
    YAMAGUCHI, K
    GOTO, S
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) : 1118 - 1122
  • [6] In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis
    Yamamoto, T
    Amitani, R
    Suzuki, K
    Tanaka, E
    Murayama, T
    Kuze, F
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) : 426 - 428
  • [7] INVITRO AND INVIVO ACTIVITIES OF KRM-1648, A NEWLY SYNTHESIZED BENZOXAZINORIFAMYCIN, AGAINST MYCOBACTERIUM-MARINUM
    YAMAMOTO, Y
    SAITO, H
    TOMIOKA, H
    SATO, K
    YAMANE, T
    YAMASHITA, K
    HOSOE, K
    HIDAKA, T
    ZENTRALBLATT FUR BAKTERIOLOGIE-INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY VIROLOGY PARASITOLOGY AND INFECTIOUS DISEASES, 1992, 277 (02): : 204 - 209
  • [8] IN-VITRO AND IN-VIVO ACTIVITIES OF LEVOFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS
    JI, BH
    LOUNIS, N
    TRUFFOTPERNOT, C
    GROSSET, J
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) : 1341 - 1344
  • [9] In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin -: Anti-mycobacterial activity of KRM-1648
    Dhople, AM
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2001, 51 (06): : 501 - 505
  • [10] Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice
    Reddy, MV
    LunaHerrera, J
    Daneluzzi, D
    Gangadharam, PRJ
    TUBERCLE AND LUNG DISEASE, 1996, 77 (02): : 154 - 159